Skip to content
10-Q

Quarterly Report

NGM BIOPHARMACEUTICALS INC

0001628280-23-015766

← back to feed
Filed
May 4, 2023 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 1, 2023 82.36M sh
Shares Diluted Q1 2023 · Mar 31, 2023 82.01M sh
Shares Diluted Q1 2023 · Mar 31, 2022 78.02M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$41.83M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$35.74M
Short Term Investments Q1 2023 · Mar 31, 2023 $163.46M
Short Term Investments Q1 2023 · Dec 31, 2022 $198.04M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $67.55M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $73.46M
Stockholders Equity Q1 2023 · Mar 31, 2023 $220.93M
Stockholders Equity Q1 2023 · Dec 31, 2022 $259.56M
Stockholders Equity Q1 2023 · Mar 31, 2022 $311.14M
Stockholders Equity Q1 2023 · Dec 31, 2021 $335.65M
Current Liabilities Q1 2023 · Mar 31, 2023 $37.9M
Current Liabilities Q1 2023 · Dec 31, 2022 $47.84M
Total Liabilities Q1 2023 · Mar 31, 2023 $37.9M
Total Liabilities Q1 2023 · Dec 31, 2022 $47.84M
Current Assets Q1 2023 · Mar 31, 2023 $242.53M
Current Assets Q1 2023 · Dec 31, 2022 $288.86M
Total Assets Q1 2023 · Mar 31, 2023 $258.84M
Total Assets Q1 2023 · Dec 31, 2022 $307.4M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.58
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.42
Eps Basic Q1 2023 · Mar 31, 2023 −$0.58
Eps Basic Q1 2023 · Mar 31, 2022 −$0.42
Sga Expense Q1 2023 · Mar 31, 2023 $11.58M
Sga Expense Q1 2023 · Mar 31, 2022 $10.72M
Rd Expense Q1 2023 · Mar 31, 2023 $40.86M
Rd Expense Q1 2023 · Mar 31, 2022 $42.81M
Net Income Q1 2023 · Mar 31, 2023 −$47.65M
Net Income Q1 2023 · Mar 31, 2022 −$32.45M
Operating Income Q1 2023 · Mar 31, 2023 −$50.19M
Operating Income Q1 2023 · Mar 31, 2022 −$32.58M
Revenue Q1 2023 · Mar 31, 2023 $2.25M
Revenue Q1 2023 · Mar 31, 2022 $20.95M